Used in the treatment of certain types of brain tumors, particularly low-grade gliomas that have specific genetic mutations such as IDH1 or IDH2. It works by inhibiting the mutant forms of the isocitrate dehydrogenase (IDH) enzymes, which are involved in the abnormal metabolism of cancer cells. By blocking these enzymes, the compound helps restore normal cellular differentiation and reduces the production of an oncometabolite called 2-hydroxyglutarate (2-HG), thereby slowing or stopping tumor growth. It is notable for its ability to cross the blood-brain barrier, making it effective in targeting central nervous system tumors. Currently investigated in clinical trials for its efficacy and safety in patients with recurrent or residual gliomas.